Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P14927
UPID:
QCR7_HUMAN
Alternative names:
Complex III subunit 7; Complex III subunit VII; QP-C; Ubiquinol-cytochrome c reductase complex 14 kDa protein
Alternative UPACC:
P14927; E5RJU0; Q6FGD1
Background:
Cytochrome b-c1 complex subunit 7, also known as Complex III subunit 7, plays a pivotal role in the mitochondrial electron transport chain, driving oxidative phosphorylation. This protein is a component of the ubiquinol-cytochrome c oxidoreductase, facilitating electron transfer and proton translocation across the mitochondrial membrane, essential for ATP synthesis.
Therapeutic significance:
Mutations in Cytochrome b-c1 complex subunit 7 are linked to Mitochondrial complex III deficiency, nuclear type 3, characterized by a spectrum of symptoms including encephalopathy and liver dysfunction. Targeting this protein could offer novel therapeutic avenues for treating mitochondrial disorders.